Results 11 to 20 of about 120,343 (298)

Drug Design and Development for Rare Hematologic Diseases. [PDF]

Pharmaceuticals (Basel), 2023
The last decade has seen an exponential increase in therapeutic options for rare hematologic ...
Fattizzo B, Capecchi M, Motta I.
europepmc   +2 more sources

COVID-19 in Patients with Hematologic Diseases. [PDF]

Biomedicines, 2022
first_pagesettingsOrder Article Reprints Open AccessReview COVID-19 in Patients with Hematologic Diseases by Ilaria Carola Casetti 1ORCID,Oscar Borsani 1,2ORCID andElisa Rumi 1,2,*ORCID 1 Department of Molecular Medicine, University of Pavia, 27100 ...
Casetti IC, Borsani O, Rumi E.
europepmc   +3 more sources

Invasive Fusariosis in Patients with Hematologic Diseases. [PDF]

J Fungi (Basel), 2021
Fusarium species are filamentous fungi widely encountered in nature, and may cause invasive disease in patients with hematologic conditions. Patients at higher risk are those with acute leukemia receiving induction remission chemotherapy or allogeneic ...
Nucci M, Barreiros G, Akiti T, Anaissie E, Nouér SA.   +4 more
europepmc   +2 more sources

Mucormycosis in Hematologic Malignancies: Clinical Follow-Up and Treatment Results [PDF]

, 2021
Introduction:Mucormycosis is an aggressive-progressive invasive fungal infection caused by mold fungi in the division of mucorales of the zygomycetes class with high mortality, and is the most common fungal infection in patients with hematologic ...
Mehmet Hilmi Doğu, Nagehan Didem Sarı, Istemi Serin, Tolga Kırgezen   +3 more
core   +1 more source

Outcomes of splenectomy for hematologic diseases-a single center experience

, 2021
© 2021, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.Splenectomy is a standard, effective and approved approach to the treatment of patients with failed medical treatment who develop recurrent, refractory or chronic diseases.
Kotan, Mehmet Çetin, Çallı, İskan, Aslan, Fırat, İliklerden, Ümit Haluk, Kızıltan, Remzi   +4 more
core   +1 more source

Microbiota and Hematological Diseases

International Journal of Hematology-Oncology and Stem Cell Research, 2022
The microbiota is directly involved in the host metabolic process, as well as in immune response modulation and recruitment of different cells typology in the inflammatory site. Human microbiota modification (dysbiosis) is a condition which could be correlated with various pathologies.
openaire   +3 more sources

ANORECTAL COMPLICATIONS DURING NEUTROPENIC PERIOD IN PATIENTS WITH HEMATOLOGIC DISEASES [PDF]

, 2016
Background: Neutropenic patients are susceptible to any anorectal disease, and symptomatic anorectal disease afflicts 2-32% of oncology patients. Perianal infections are the most feared complication, considering the lack of natural defense against ...
Kozanoglu, Ilknur, Asma, Suheyl, Kasar, Mutlu, Solmaz, Soner, Korur, Asli, Soner Solmaz, Yeral, Mahmut, Buyukkurt, Nurhilal, Gereklioglu, Cigdem, Ozdogu, Hakan, Boga, Can   +10 more
core   +1 more source

Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond

, 2022
: Complement is an elaborate system of innate immunity. Genetic variants and autoantibodies leading to excessive complement activation are implicated in a variety of human diseases. Among them, the hematologic disease paroxysmal nocturnal hemoglobinuria (
Gavriilaki, Eleni, de Latour, Régis Peffault, Risitano, Antonio Maria   +2 more
core   +1 more source

DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia

Experimental Hematology & Oncology, 2022
Acute myeloid leukemia (AML) is a complex, heterogeneous malignant hematologic disease. Although multiple prognostic-related genes gave been explored in previous studies, there are still many genes whose prognostic value remains unclear. In this study, a
Xueqian Li, Jiaqian Qi, Xiaofei Song, Xiaoyan Xu, Tingting Pan, Hong Wang, Jingyi Yang, Yue Han   +7 more
doaj   +1 more source

Expert consensus on the off-label use in China of drugs for rare hematologic diseases (2024 edition). [PDF]

Front Pharmacol
Drug package inserts are a crucial foundation for clinical medication practices and serve as the legal basis for guiding rational drug use and ensuring patient safety and efficacy.
Zhao B, Zhou X, Zheng P, Zhang B, Feng X, Chen J, Cai L, Chen Y, He L, Su J, Cheng S, Zeng Y, Li G, Ji B, Wu J, Feng W, Liu M, Jin Y, Liu T, Mo X, Wu J, Wu H, Zhang H, Zheng Z, Zheng Z, Sun J, Li Y, Guangdong Pharmaceutical Association, Hematology Group of Rare Disease Expert Committee of Guangdong Pharmaceutical Association.   +28 more
europepmc   +2 more sources